82
Participants
Start Date
March 27, 2017
Primary Completion Date
November 13, 2017
Study Completion Date
November 13, 2017
VIBLOK barrier cream
VIBLOK safety and performance has not been proven yet in humans with an HSV-2 infection.
EB FlevoResearch, Almere Stad
PT&R, Beek
EB UtrechtResearch, Utrecht
Lead Sponsor
Collaborators (1)
Applied Clinical Services BV
UNKNOWN
UMC Utrecht
OTHER
University of Rotterdam, The Netherlands
OTHER
University of Washington
OTHER
EB FlevoResearch BV
UNKNOWN
PreCare Trial & Recruitment B.V.
UNKNOWN
CLJI Worldwide
INDUSTRY